New functional activities for the p21 family of CDK inhibitors von LaBaer, J, Garrett, M D, Stevenson, L F, Slingerland, J M, Sandhu, C, Chou, H S, Fattaey, A, Harlow, E

Volltext

Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein von HELIN, K, HARLOW, E, FATTAEY, A

Volltext

Reverse Two-Hybrid and One-Hybrid Systems to Detect Dissociation of Protein-Protein and DNA-Protein Interactions von Vidal, Marc, Brachmann, Rainer K., Fattaey, Ali, Harlow, Ed, Boeke, Jef D.

Volltext

Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation von HELIN, K, CHIN-LEE WU, FATTAEY, A. R, LEES, J. A, DYNLACHT, B. D, CHIDI NGWU, HARLOW, E

Volltext

Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases von Barvian, Mark, Boschelli, Diane H, Cossrow, Jennifer, Dobrusin, Ellen, Fattaey, Ali, Fritsch, Alex, Fry, David, Harvey, Patricia, Keller, Paul, Garrett, Michelle, La, Frances, Leopold, Wilbur, McNamara, Dennis, Quin, Maire, Trumpp-Kallmeyer, Susanne, Toogood, Peter, Wu, Zhipei, Zhang, Erli

Volltext

Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein von LIANG ZHU, VAN DEN HEUVEL, S, HELIN, K, ALI FATTAEY, EWEN, M, LIVINGSTON, D, DYSON, N, HARLOW, E

Volltext

Analyses of Single-Amino-Acid Substitution Mutants of Adenovirus Type 5 E1B-55K Protein von Shen, Y, Kitzes, G, Nye, J A, Fattaey, A, Hermiston, T

Volltext

Independent regions of adenovirus E1A are required for binding to and dissociation of E2F-protein complexes von FATTAEY, A. R, HARLOW, E, HELIN, K

Volltext

137 Preclinical characterization of ACTB-1010, an orally activity Aurora kinase inhibitor von Burd, A, Kunkel, L, Fattaey, A

Volltext

141 ACTB-1003 - a unique oral pan FGFR and PI3K pathway inhibitor with divergent modes of activity von Burd, A, Whiteside, M, Castillo, J, Kunkel, L, Fattaey, A

Volltext

Analysis of p107-associated proteins: p107 associates with a form of E2F that differs from pRB-associated E2F-1 von DYSON, N, DEMBSKI, M, FATTAEY, A, CHIDI NGWU, EWEN, M, HELIN, K

Volltext

Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents von Johnson, Leisa, Shen, Annie, Boyle, Larry, Kunich, John, Pandey, Kusum, Lemmon, Marilyn, Hermiston, Terry, Giedlin, Marty, McCormick, Frank, Fattaey, Ali

Volltext

ACTB-1003: An oral kinase inhibitor targeting cancer mutations (FGFR), angiogenesis (VEGFR2, TEK), and induction of apoptosis (RSK and p70S6K) von Patel, K., Fattaey, A., Burd, A.

Volltext

An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells von Bischoff, James R., Kirn, David H., Williams, Angelica, Heise, Carla, Horn, Sharon, Muna, Mike, Ng, Lelia, Nye, Julie A., Sampson-Johannes, Adam, Fattaey, Ali, McCormick, Frank

Volltext

Human Myt1 Is a Cell Cycle-regulated Kinase That Inhibits Cdc2 but Not Cdk2 Activity von Booher, Robert N., Holman, Patricia S., Fattaey, Ali

Volltext

CDK inhibition and cancer therapy von Garrett, Michelle D, Fattaey, Ali

Volltext

A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F von Helin, Kristian, Lees, Jacqueline A., Vidal, Marc, Dyson, Nicholas, Harlow, Ed, Fattaey, Ali

Volltext

Pharmacokinetic and pharmacodynamic analysis of gastric cancer patients treated with telatinib von Burd, A., Castillo, J., Whiteside, M., White, M., Ajani, J. A., Fattaey, A., Kunkel, L. A.

Volltext

Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6 von Fry, D W, Bedford, D C, Harvey, P H, Fritsch, A, Keller, P R, Wu, Z, Dobrusin, E, Leopold, W R, Fattaey, A, Garrett, M D

Volltext

Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in pa... von Alsina, M., Ko, A. H., Garcia De Paredes, M., Rivera, F., Schwartzberg, L. S., Fattaey, A., Kunkel, L. A., Tabernero, J., Ajani, J. A.

Volltext